Boehringer Ingelheim Patents – Insights & Stats

Boehringer Ingelheim has a total of 593 patents globally, out of which 275 have been granted. Of these 593 patents, more than 23% patents are active. United States of America is where Boehringer Ingelheim has filed the maximum number of patents, followed by Europe and Canada. Parallelly, USA seems to be the main focused R&D center and Germany is the origin country of Boehringer Ingelheim.

Boehringer Ingelheim was founded in 1885 by Albert Boehringer. Boehringer Ingelheim operates as a pharmaceutical company. The Company researches, develops, and manufactures pharmaceutical products, as well as offers prescription medicines and consumer health care products for human and animal health. Boehringer Ingelheim serves clients worldwide.

Read about some of the most popular patents of Boehringer Ingelheim which have been covered by us in this article and also you can find Boehringer Ingelheim patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Boehringer Ingelheim patent portfolio.

How many patents does the Founder and CEO of Boehringer Ingelheim have?

The Founder Albert Boehringer have 0 patents and the CEO Jean-Michel Boers have 0 patents.

How many patents does Boehringer Ingelheim have?

Boehringer Ingelheim has a total of 593 patents globally. These patents belong to 136 unique patent families. Out of 593 patents, 140 patents are active.

How Many Patents did Boehringer Ingelheim File Every Year?

Boehringer Ingelheim Patents Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantBoehringer Ingelheim Applications FiledBoehringer Ingelheim Patents Granted
2011520
20121229
2013523
201417
20158
201615
201735
201814
201932
202015
202181

Which Boehringer Ingelheim Drug Patents are Expiring in the Next 10 Years?

The patent no. US10406172B2 which is expiring in Jun, 2030, describes managing type 2 diabetes involves using an SGLT2 inhibitor, a DPPIV inhibitor, and another antidiabetic agent to prevent, slow, delay, or treat metabolic disorders in patients.

Given below is the list of few drugs patented by Boehringer Ingelheim accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.

Drug NamePatent NumberPatent TitlePatent Expiration
Trijardy XrUS10406172B2Pharmaceutical composition…Jun, 2030
JentaduetoUS10022379B2DPP-IV inhibitor combined with a…Apr, 2029
TradjentaUS10034877B2Treatment for diabetes in patients…Aug, 2029
GlyxambiUS11033552B2DPP IV inhibitor formulationsMay, 2027
Jentadueto XrUS8883805B2Process for the preparation of…May, 2026

How many Boehringer Ingelheim patents are Alive/Dead?

Worldwide Patents

Boehringer Ingelheim Patents Portfolio

How Many Patents did Boehringer Ingelheim File in Different Countries?

Boehringer Ingelheim Worldwide Patents

Countries in which Boehringer Ingelheim Filed Patents

CountryPatents
United States Of America43
Europe42
Canada26
China25
Australia24
Hong Kong (S.A.R.)20
Korea (South)20
India19
Japan18
Spain18
Germany18
Austria16
Portugal15
Ukraine15
Brazil15
Mexico15
Russia13
Denmark13
Argentina12
Chile12
Philippines12
Indonesia11
Israel10
Poland10
New Zealand10
South Africa10
Viet Nam9
Taiwan8
Singapore8
Peru7
Cyprus7
Malaysia7
Slovenia6
United Kingdom6
Ecuador4
Uruguay3
Norway3
Morocco2
Turkey2
Tunisia2
Serbia2
Colombia2
Croatia2
Hungary2
Finland1
Guatemala1
Luxembourg1
Dominican Republic1
Costa Rica1
Lithuania1
Africa1
Honduras1
Albania1
Montenegro1
Panama1

Where are Research Centers of Boehringer Ingelheim Patents Located?

Research Centers of Boehringer Ingelheim Patents

10 Best Boehringer Ingelheim Patents

US6391314B1 is the most popular patent in the Boehringer Ingelheim portfolio. It has received 335 citations so far from companies like Zoetis Services Llc, Sbc Virbac Limited and Quantum Genetics Ireland Limited.

Below is the list of 10 most cited patents of Boehringer Ingelheim:

Publication NumberCitation Count
US6391314B1335
US6368601B1203
WO2004096777A1132
US6660272B2127
US7122192B293
US7192594B288
US7144698B285
US7211379B282
US6776965B278
WO2004084898A170

What Percentage of Boehringer Ingelheim US Patent Applications were Granted?

Boehringer Ingelheim (Excluding its subsidiaries) has filed 738 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 439 have been granted leading to a grant rate of 65.5%.

Below are the key stats of Boehringer Ingelheim patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Boehringer Ingelheim?

Law FirmTotal ApplicationsSuccess Rate
C O Vp Ip Legal63365.53%
Robert P Raymond1190.91%
Dernier Ip Law Llc10100.00%
Potomac Law Group Pllc760.00%
Wolf Greenfield & Sacks Pc6100.00%
C O Ah Patent Department560.00%
Additon Pendleton & Witherspoon Pa40.00%
Sterne Kessler Goldstein & Fox Pllc450.00%
Alston & Bird Llp333.33%
Boehringer Ingelheim Animal Health Usa Inc30%

EXCLUSIVE INSIGHTS COMING SOON!

What are Boehringer Ingelheim key innovation segments?

What Technologies are Covered by Boehringer Ingelheim?

The chart below distributes patents filed by Boehringer Ingelheim in different countries on the basis of the technology protected in patents. It also represents the markets where Boehringer Ingelheim thinks it’s important to protect particular technology inventions.

R&D Focus: How has Boehringer Ingelheim search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Boehringer Ingelheim?

Related Articles

Rapoo Patents – Insights & Stats (Updated 2024)

Rapoo has a total of 562 patents globally, out of which 507 have been granted. Of these 562 patents, more than 31% patents are active. China is where Rapoo has filed the maximum number of patents, followed by Europe (EPO) and United States of America. Parallelly, China seems to be

Read More »

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.